Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Total Current Liabilities (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Total Current Liabilities for 15 consecutive years, with $3.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities fell 25.01% year-over-year to $3.4 million, compared with a TTM value of $3.4 million through Sep 2025, down 25.01%, and an annual FY2024 reading of $3.7 million, up 43.76% over the prior year.
  • Total Current Liabilities was $3.4 million for Q3 2025 at BioRestorative Therapies, down from $3.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $14.7 million in Q1 2022 and bottomed at $363822.0 in Q4 2021.
  • Average Total Current Liabilities over 5 years is $4.8 million, with a median of $3.7 million recorded in 2024.
  • The sharpest move saw Total Current Liabilities crashed 92.99% in 2021, then soared 1544.22% in 2022.
  • Year by year, Total Current Liabilities stood at $363822.0 in 2021, then skyrocketed by 1544.22% to $6.0 million in 2022, then crashed by 56.41% to $2.6 million in 2023, then skyrocketed by 43.76% to $3.7 million in 2024, then decreased by 8.34% to $3.4 million in 2025.
  • Business Quant data shows Total Current Liabilities for BRTX at $3.4 million in Q3 2025, $3.7 million in Q2 2025, and $4.2 million in Q1 2025.